Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GBA1 | P04062 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17478811 | 0.97 | GBA1 (0.50) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17479170 | 0.94 | MAPT (0.48) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17478822 | 0.91 | GBA1 (0.43) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17478641 | 0.89 | GBA1 (0.44) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17478973 | 0.89 | MAPT (0.47) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17478707 | 0.89 | GBA1 (0.44) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17479041 | 0.89 | GBA1 (0.45) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17478965 | 0.89 | GBA1 (0.45) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17479139 | 0.89 | GBA1 (0.43) | MAPTSMN1; SMN2GBA1KDM4EGAA | |
| SCHEMBL17479305 | 0.88 | GBA1 (0.43) | MAPTSMN1; SMN2GBA1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | claimed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | claimed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | claimed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | claimed |
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | MAPT 575/4885SMN1; SMN2 2459/4885GBA1 1736/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | MAPT 575/4885SMN1; SMN2 2459/4885GBA1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.